Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
· manilatimes.net
Revenue for the first half of 2026 increased 29%year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026 ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as 'Ascentage Pharma,” the 'Company,” 'we,” 'us” or 'our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today reported its unaudited financial results for the six months ended June 30, 2026, and provided updates on key ongoing clinical programs and commercial activities.
Revenue for the first half of 2026 increased 29%year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales.
Expand...